Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Intimation for grant of Employee Stock Options '.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has informed the stock exchanges that its Nomination and Remuneration Committee approved the grant of 11,52,500 Employee Stock Options (ESOPs) on March 9, 2026. These options are issued under the company's existing ESOP Plan, 2022, at an exercise price of Rs. 139 per option. Each option is convertible into one equity share of Rs. 2 face value. The options will vest in 4 equal annual tranches, starting from the first anniversary of the grant date. The intimation has been signed by the Company Secretary, Pratham Rawal.
This is a routine ESOP grant that will lead to a minor equity dilution once options are exercised, but since the exercise price of Rs. 139 is above current market levels, the dilution impact is limited. No immediate material impact on shareholders is expected.